Zagonel V, Tirelli U, Veronesi A, Galligioni E, Tumolo S, Roncadin M, Carbone A, Grigoletto E
Blut. 1986 Jan;52(1):59-61. doi: 10.1007/BF00320143.
Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.
替尼泊苷已在慢性淋巴细胞白血病（CLL）的II期临床试验中进行了评估。在连续纳入该研究并接受替尼泊苷治疗（每周100mg/m²）的16例CLL患者中，未观察到客观缓解。毒性一般较轻，主要为血液学毒性。在此剂量和给药方案下，替尼泊苷在CLL中是一种无效药物。
